One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration.
Age-related macular degeneration
Anti-VEGF
Faricimab
Poor responder
Switcher
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
29
07
2024
accepted:
11
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
aheadofprint
Résumé
This study assessed the efficacy, durability, and safety of faricimab in patients with neovascular age-related macular degeneration (nAMD), previously treated with aflibercept or ranibizumab with unsatisfactory results. This was a single-center, prospective cohort study of all consecutive patients with nAMD switched to intravitreally administered faricimab from traditional anti-vascular endothelial growth factor (anti-VEGF) treatments between September 2022 and April 2023 because of unsatisfactory response (maximal fluid-free interval ≤ 8 weeks). Faricimab was administered with a loading dose of four 4-weekly injections, followed by a treat-and-extend regimen. The primary outcome measures were maximum fluid-free interval after the switch and last assigned treatment interval. Secondary outcome measures included best-corrected visual acuity (BCVA) and structural optical coherence tomography parameters. Thirty-three eyes of 33 patients were included. Patients were followed for a median of 72 weeks [interquartile range 61, 76]. Median maximum fluid-free treatment interval after switch to faricimab and the last assigned interval were significantly longer than before the switch (7 vs. 4 weeks, p < 0.001 and 8 vs. 5 weeks, p < 0.001, respectively). Significant improvements in central subfield thickness (353 vs. 281 µm), macular volume (2.46 vs. 2.16 mm Faricimab improved anatomical outcomes and allowed longer treatment intervals in patients with nAMD previously treated with other anti-VEGF therapies with unsatisfactory response, reducing treatment burden. A favorable safety profile was observed.
Identifiants
pubmed: 39340634
doi: 10.1007/s40123-024-01036-4
pii: 10.1007/s40123-024-01036-4
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721–31. https://doi.org/10.1038/eye.2015.48 .
doi: 10.1038/eye.2015.48
pubmed: 25882328
Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40. https://doi.org/10.1016/S0140-6736(22)00010-1 .
doi: 10.1016/S0140-6736(22)00010-1
pubmed: 35085502
Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: 2-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024. https://doi.org/10.1016/j.ophtha.2024.02.014 . (S0161-6420(24)00134–9).
doi: 10.1016/j.ophtha.2024.02.014
pubmed: 39182627
Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. 2023;37:3574–81. https://doi.org/10.1038/s41433-023-02553-5 .
doi: 10.1038/s41433-023-02553-5
pubmed: 37173428
pmcid: 10686385
Leung EH, Oh DJ, Alderson SE, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287–93. https://doi.org/10.2147/OPTH.S409822 .
doi: 10.2147/OPTH.S409822
pubmed: 37181079
pmcid: 10167970
Cheng AM, Joshi S, Banoub RG, et al. Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus. 2023;15:e40100. https://doi.org/10.7759/cureus.40100 .
doi: 10.7759/cureus.40100
pubmed: 37425528
pmcid: 10328548
Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201–8. https://doi.org/10.2147/OPTH.S424315 .
doi: 10.2147/OPTH.S424315
pubmed: 37547172
pmcid: 10404054
Kishi M, Miki A, Kamimura A, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023;12:5145. https://doi.org/10.3390/jcm12155145 .
doi: 10.3390/jcm12155145
pubmed: 37568546
pmcid: 10419383
Kataoka K, Itagaki K, Hashiya N, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43–51. https://doi.org/10.1007/s00417-023-06222-x .
doi: 10.1007/s00417-023-06222-x
pubmed: 37668741
Szigiato A, Mohan N, Talcott KE, et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina. 2024;8:10–7. https://doi.org/10.1016/j.oret.2023.08.018 .
doi: 10.1016/j.oret.2023.08.018
pubmed: 37673396
Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652–6. https://doi.org/10.1007/s10384-023-01024-4 .
doi: 10.1007/s10384-023-01024-4
pubmed: 37861941
Pandit SA, Momenaei B, Wakabayashi T, et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8:360–6. https://doi.org/10.1016/j.oret.2023.10.018 .
doi: 10.1016/j.oret.2023.10.018
pubmed: 37913992
Raimondi R, Falfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2023. https://doi.org/10.1016/j.oret.2023.11.015 . (S2468-6530(23)00623–1).
doi: 10.1016/j.oret.2023.11.015
pubmed: 38040055
Grimaldi G, Cancian G, Rizzato A, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262:1151–9. https://doi.org/10.1007/s00417-023-06319-3 .
doi: 10.1007/s00417-023-06319-3
pubmed: 38047930
Ng B, Kolli H, Ajith Kumar N, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life (Basel). 2024;14:193. https://doi.org/10.3390/life14020193 .
doi: 10.3390/life14020193
pubmed: 38398702
Sutter D, Anderson A, Wheatley S, Sheth V. Quantifying fluid and function in suboptimal responders switched from an anti-vascular endothelial growth factor (VEGF) to faricimab. Cureus. 2024;16:e56652. https://doi.org/10.7759/cureus.56652 .
doi: 10.7759/cureus.56652
pubmed: 38516283
pmcid: 10957152
Aljundi W, Munteanu C, Seitz B, Abdin AD. Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024. https://doi.org/10.1007/s00417-024-06485-y .
doi: 10.1007/s00417-024-06485-y
pubmed: 38607409
Takahashi H, Inoda S, Takahashi H, et al. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci Rep. 2024;14:9087. https://doi.org/10.1038/s41598-024-59894-8 .
doi: 10.1038/s41598-024-59894-8
pubmed: 38643252
pmcid: 11032343
Eckardt F, Lorger A, Hafner M, et al. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration. Sci Rep. 2024;14:9600. https://doi.org/10.1038/s41598-024-59632-0 .
doi: 10.1038/s41598-024-59632-0
pubmed: 38671028
pmcid: 11053147
Aljundi W, Daas L, Suffo S, et al. First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics. 2024;16:470. https://doi.org/10.3390/pharmaceutics16040470 .
doi: 10.3390/pharmaceutics16040470
pubmed: 38675131
pmcid: 11053849
Hahn P. ASRS 2023 preferences and trends membership survey. Chicago: American Society of Retina Specialists; 2023.
Brinkmann M, Viggiano P, Boscia G, et al. Analysis of choriocapillaris reperfusion topography following faricimab treatment for neovascular age-related macular degeneration in non-treatment-naïve patients. Diagnostics. 2024;14(9):901. https://doi.org/10.3390/diagnostics14090901 .
doi: 10.3390/diagnostics14090901
pubmed: 38732315
pmcid: 11083352
Ashraf M, Banaee T, Silva FQ, Singh RP. Switching anti-vascular endothelial growth factors in refractory neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018;49:166–70. https://doi.org/10.3928/23258160-20180221-03 .
doi: 10.3928/23258160-20180221-03
pubmed: 29554383
Romano F, Cozzi E, Airaldi M, et al. Ten-year incidence of fibrosis and risk factors for its development in neovascular age-related macular degeneration. Am J Ophthalmol. 2023;252:170–81. https://doi.org/10.1016/j.ajo.2023.03.033 .
doi: 10.1016/j.ajo.2023.03.033
pubmed: 37030492
Frenkel REP, Shapiro H, Stoilov I. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision. Br J Ophthalmol. 2016;100:1052–7. https://doi.org/10.1136/bjophthalmol-2015-307575 .
doi: 10.1136/bjophthalmol-2015-307575
pubmed: 26541435
Michalska-Małecka K, Kałużny J, Nowak M, et al. Evaluation of retinal function improvement in neovascular age-related macular degeneration after intravitreal aflibercept injections with the use of the assessment of retinal sensitivity: the use of the assessment of retinal sensitivity in anti-VEGF treatment—a STROBE-compliant observational study. Medicine (Baltimore). 2019;98:e17599. https://doi.org/10.1097/MD.0000000000017599 .
doi: 10.1097/MD.0000000000017599
pubmed: 31689763
Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:83–90. https://doi.org/10.1007/s10384-023-01040-4 .
doi: 10.1007/s10384-023-01040-4
pubmed: 38244172
Mukai R, Kataoka K, Tanaka K, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747. https://doi.org/10.1038/s41598-023-35759-4 .
doi: 10.1038/s41598-023-35759-4
pubmed: 37253802
pmcid: 10229564
Tanaka A, Hata M, Tsuchikawa M, et al. Short-term outcomes of 3 monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration. Clin Ophthalmol Auckl NZ. 2024;18:507–16. https://doi.org/10.2147/OPTH.S448507 .
doi: 10.2147/OPTH.S448507
Stanga PE, Valentín-Bravo FJ, Stanga SEF, et al. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37:3282–9. https://doi.org/10.1038/s41433-023-02505-z .
doi: 10.1038/s41433-023-02505-z
pubmed: 36959312